Immunotherapy niche Position Multimeric Biotherapeutics as a specialist in TNFSF-based multi-trimer proteins for cancer and vaccine adjuvant applications, highlighting MegaCD40L and follow-on CD137L and OX40L programs to attract partnerships with immunotherapy and vaccinology players.

Clinical collaboration potential Leverage NIH-supported programs and preclinical data on MegaCD40L to pursue co-development or sponsored research opportunities with academic centers and biotech firms seeking novel vaccine adjuvants or tumor immunotherapy enhancers.

Therapeutic expansion Identify opportunities to couple MegaCD40L with ovarian cancer trials or other oncology indications, as well as vaccine platforms, to broaden clinical pathways and attract large-pharma interest in combination strategies.

Strategic funding angles Emphasize early-stage revenue potential from niche immunotherapy assets and explore grant-led financing, non-dilutive funding, and milestone-driven partnerships to de-risk early development for potential licensees.

SMB-to-Scale path Highlight the company's small size and agility as a strength for rapid collaboration with bigger biopharma partners, while outlining a clear BD plan to access candidate expansion, manufacturing readiness, and strategic alliances.